홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Erlotinib Hydrochloride

HCID 176871
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
183319-69-9
표준 SMILES
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl
InChIKey
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
분자식
C22H24ClN3O4
평균 분자량
429.9 g/mol
단동위원소 질량
429.14553393

개요

Erlotinib Hydrochloride is the hydrochloride salt of a quinazoline derivative with antineoplastic properties. Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.

이름 및 식별자

우선 이름
Erlotinib Hydrochloride
IUPAC
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine;hydrochloride
영어명
Erlotinib hydrochloride
분자식
C22H24ClN3O4
분자량
429.9

이름 및 동의어

Erlotinib hydrochloride183319-69-9erlotinib HClTarcevaOSI-774OSI 774HCl, ErlotinibCP 35877411C erlotinibCP-358,774-01DA87705X9KHydrochloride, Erlotinib
이름 더 보기
ErLErlotinib, Hydrochloride SaltCS-491RG-1415RO-0508231
CP-3584-(m-Ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline monohydrochlorideCP-358774CHEBI:53509DTXSID10171412CP-358774-01NSC 718781NSC718781

데이터베이스 식별자

CAS
183319-69-9
PubChem CID
176871
DTXSID
DTXSID10171412
ChEMBL
CHEMBL1079742
UNII
DA87705X9K
EC Number
620-491-0

물성

구조 계산 물성

극성 표면적
74.7 Ų
수소 결합 공여자 수
2
수소 결합 수용자 수
7
회전 가능 결합 수
11
무거운 원자 수
30
형식 전하
0
복잡도
525

실험 및 물리화학적 성질

Human Drugs · 3건

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

물리화학적 성질

녹는점
223 · 223-225°C
저장 조건
-20 °C · Inert atmosphere,Store in freezer, under -20°C
용해도
DMSO에 용해됩니다(가온 시 최대 18mg/ml).
산도 계수 (pKa)
pKa (25°): 5.42
물리적 상태
노란색 가루.
색상
흰색 또는 황백색
안정성
1 · 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO의 솔루션은 -20°에서 최대 3개월 동안 보관할 수 있습니다.
InChI
InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
InChIKey
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
SMILES
C12C=C(OCCOC)C(OCCOC)=CC=1N=CN=C2NC1=CC=CC(=C1)C#C.Cl

화학적 성질

Off-White Solid

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H302 (91.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P318, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 12 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (91.7%)

독성 정보

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Erlotinib hydrochloride

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

안전 데이터

wgk
WGK 3
rtecs
VA0971200
HS 번호
29335990
safety_code
24/25
Hazard Classifications
Acute Tox. 4 Oral
스토리지 클래스
11 - Combustible Solids

화학 및 산업

약리 정보

FDA Pharmacological Classification · 2건

ERLOTINIB HYDROCHLORIDE

Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]

MeSH Pharmacological Classification · 2건

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

응용 분야 · 2건

용도Erlotinib hydrochloride (V), a quinazoline derived small molecule inhibitor of epidermal growth factor receptor (EDGFR) tyrosine kinase, was approved in November, 2004, for the treatment of advanced or metastatic non-smallcell lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development initiated in collaboration with OSI, which assumed full rights to the drug when Pfizer merged with Warner Lambert. Subsequently, Genentech/Roche went into licensing agreement with OSI to develop and market the drug in the US and Worldwide.

일반 설명Erlotinib is available as 25-, 100-, and 150-mg tablets fororal administration and is used after failure of first-linetherapy in metastatic NSCLC and as first-line therapy incombination with gemcitabine in the treatment of metastaticpancreatic cancer, and in treating malignant gliomas.The structural similarity to gefitnib imparts similar pharmacokineticbehavior with bioavailability of 60% and proteinbinding of 93%. The agent is extensively metabolizedprimarily by CYP3A4. Three major metabolic pathwayshave been identified, involving oxidative-O-demethylationof the side chains followed by further oxidation to give thecarboxlic acids, oxidation of the acetylene functionalityto give a carboxylic acid, and aromatic hydroxylation ofthe phenyl ring para to the electron-donating nitrogen. Themetabolites are primarily eliminated in the feces, and theterminal half-life is 36 hours.The major toxicities seenwith the agent are dose-limiting skin rash and diarrhea.Other common adverse effects include shortness of breath,fatigue, and nausea.

상·하류 제품 정보

관련 반응

58건
반응 기록 만들기
HRID 238993 반응식
HRID 238993생성물로
HRID 238994 반응식
HRID 238994생성물로
HRID 238995 반응식
HRID 238995생성물로
HRID 238996 반응식
HRID 238996생성물로
HRID 238997 반응식
HRID 238997생성물로
HRID 238998 반응식
HRID 238998생성물로
HRID 239001 반응식
HRID 239001생성물로
HRID 243531 반응식
HRID 243531생성물로
이전1 / 8 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

하류 제품

엘로티닙

추가 설명

정의ChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.